Stock listing
BOATS:APMD Apnimed, Inc. Stock
US listing (BOATS) of Apnimed, Inc. · home listing NASDAQ:APMD
Follow Apnimed, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:APMD
$16.09 USD -1.36 (-7.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:APMD
- Day range
- $15.95 – $17.73 USDNov 20, 2026
- Volume
- 248,586 sharesNov 20, 2026
- Market cap
- $669.8M USDAt the close on Nov 20, 2026 · price × 41.63M shares outstanding
- Traded on an average day
- $10.22M USDMedian day 340,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:APMD · Home | $16.09 USD | -1.36 (-7.8%) | 248,586 | $17.08 | $17.73 | $15.95 | $17.45 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:APMD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $16.09 | -1.36 | -7.8% | $17.08 | $17.73 | $15.95 | 248,586 | |
| $17.45 | -0.35 | -2.0% | $17.80 | $19.06 | $17.41 | 296,982 | |
| $17.80 | +1.52 | +9.3% | $16.03 | $17.89 | $15.86 | 395,528 | |
| $16.28 | -0.64 | -3.8% | $16.05 | $17.10 | $15.80 | 256,887 | |
| $16.92 | +0.29 | +1.7% | $17.41 | $17.46 | $16.38 | 690,802 | |
| $16.63 | -0.15 | -0.9% | $16.81 | $16.99 | $16.16 | 278,599 | |
| $16.78 | +0.92 | +5.8% | $15.99 | $16.85 | $15.26 | 194,866 | |
| $15.86 | +0.05 | +0.3% | $15.67 | $16.58 | $15.21 | 378,259 | |
| $15.81 | +0.71 | +4.7% | $15.32 | $16.22 | $15.09 | 290,121 | |
| $15.10 | +0.94 | +6.6% | $14.26 | $15.41 | $14.11 | 225,337 | |
| $14.16 | -1.14 | -7.5% | $15.37 | $15.52 | $13.88 | 447,702 | |
| $15.30 | +0.24 | +1.6% | $15.36 | $15.97 | $14.65 | 603,554 | |
| $15.06 | -0.34 | -2.2% | $15.48 | $16.99 | $14.96 | 575,729 | |
| $15.40 | -1.00 | -6.1% | $16.55 | $16.78 | $15.09 | 530,944 | |
| $16.40 | -0.94 | -5.4% | $17.10 | $17.36 | $16.16 | 465,684 | |
| $17.34 | -1.81 | -9.5% | $19.15 | $19.19 | $17.00 | 1,011,662 | |
| $19.15 | -0.34 | -1.7% | $19.44 | $19.51 | $18.00 | 323,307 | |
| $19.49 | +0.54 | +2.8% | $19.06 | $19.75 | $18.23 | 365,456 | |
| $18.95 | -0.04 | -0.2% | $19.14 | $19.52 | $18.43 | 178,483 | |
| $18.99 | +0.46 | +2.5% | $18.50 | $19.15 | $17.84 | 277,300 | |
| $18.53 | -0.37 | -2.0% | $18.75 | $19.24 | $18.22 | 194,811 | |
| $18.90 | +0.39 | +2.1% | $18.75 | $19.57 | $18.57 | 295,456 | |
| $18.51 | +1.915 | +11.5% | $16.64 | $18.80 | $16.43 | 311,107 | |
| $16.60 | -1.165 | -6.6% | $18.00 | $18.49 | $16.52 | 264,469 | |
| $17.76 | -0.49 | -2.7% | $18.30 | $18.35 | $17.40 | 235,100 | |
| $18.25 | +1.02 | +5.9% | $17.25 | $18.76 | $17.25 | 260,200 | |
| $17.23 | -0.60 | -3.4% | $17.85 | $18.62 | $17.00 | 1,012,700 | |
| $17.83 | -0.80 | -4.3% | $18.85 | $18.85 | $17.45 | 215,600 | |
| $18.63 | +0.11 | +0.6% | $18.57 | $20.00 | $18.26 | 301,100 | |
| $18.52 | +0.30 | +1.6% | $18.18 | $19.54 | $17.80 | 268,300 | |
| $18.22 | +0.18 | +1.0% | $18.05 | $18.61 | $17.38 | 332,000 | |
| $18.04 | -0.61 | -3.3% | $18.66 | $19.40 | $17.84 | 465,600 | |
| $18.65 | -3.10 | -14.3% | $21.95 | $21.95 | $18.34 | 580,800 | |
| $21.75 | +0.24 | +1.1% | $21.70 | $22.11 | $21.10 | 340,300 | |
| $21.51 | -1.03 | -4.6% | $22.60 | $22.73 | $21.10 | 681,800 | |
| $22.54 | +0.63 | +2.9% | $21.96 | $24.50 | $21.96 | 747,400 | |
| $21.91 | -1.99 | -8.3% | $23.57 | $24.50 | $21.49 | 668,800 | |
| $23.90 | +2.23 | +10.3% | $21.48 | $24.29 | $21.48 | 669,500 | |
| $21.67 | +0.58 | +2.8% | $21.15 | $22.09 | $19.80 | 283,800 | |
| $21.09 | -0.54 | -2.5% | $22.00 | $22.77 | $20.68 | 298,700 | |
| $21.63 | -0.86 | -3.8% | $22.06 | $22.85 | $20.50 | 398,200 | |
| $22.49 | -3.02 | -11.8% | $25.44 | $25.44 | $21.60 | 858,100 | |
| $25.51 | -0.71 | -2.7% | $26.41 | $26.69 | $24.42 | 624,000 | |
| $26.22 | -2.78 | -9.6% | $28.90 | $28.90 | $23.13 | 1,507,000 | |
| $29.00 | +0.89 | +3.2% | $28.34 | $30.22 | $27.99 | 3,141,800 | |
| $28.11 | +1.02 | +3.8% | $27.47 | $29.00 | $27.15 | 355,700 | |
| $27.09 | +1.53 | +6.0% | $25.81 | $27.96 | $25.66 | 552,600 | |
| $25.56 | +0.01 | 0.0% | $25.62 | $26.83 | $25.05 | 350,400 | |
| $25.55 | -0.68 | -2.6% | $26.48 | $27.07 | $25.05 | 263,400 | |
| $26.23 | -0.57 | -2.1% | $27.07 | $27.72 | $26.19 | 207,800 | |
| $26.80 | -1.28 | -4.6% | $27.11 | $28.74 | $26.59 | 213,400 | |
| $28.08 | -0.71 | -2.5% | $28.79 | $29.46 | $27.34 | 220,000 | |
| $28.79 | +1.34 | +4.9% | $27.67 | $29.65 | $27.41 | 380,800 | |
| $27.45 | -0.36 | -1.3% | $27.36 | $28.36 | $26.44 | 232,900 | |
| $27.81 | -0.02 | -0.1% | $28.11 | $28.83 | $27.32 | 234,300 | |
| $27.83 | +0.98 | +3.6% | $27.00 | $28.75 | $26.90 | 276,600 | |
| $26.85 | +0.60 | +2.3% | $26.11 | $27.88 | $25.11 | 376,500 | |
| $26.25 | -3.46 | -11.6% | $29.71 | $30.07 | $25.60 | 475,600 | |
| $29.71 | +0.99 | +3.4% | $29.01 | $32.37 | $28.83 | 536,100 | |
| $28.72 | -0.86 | -2.9% | $29.50 | $31.09 | $28.33 | 421,700 | |
| $29.58 | +2.21 | +8.1% | $27.59 | $30.19 | $26.86 | 334,000 | |
| $27.37 | +1.74 | +6.8% | $26.60 | $29.56 | $26.01 | 480,600 | |
| $25.63 | -2.40 | -8.6% | $27.82 | $27.83 | $25.33 | 244,400 | |
| $28.03 | -0.52 | -1.8% | $28.60 | $29.56 | $27.64 | 245,300 | |
| $28.55 | -3.48 | -10.9% | $31.87 | $31.97 | $28.39 | 433,800 |
- Ticker
- BOATS:APMD
- Asset type
- Stock
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
New National Survey Found Many People With Sleep Apnea Struggle to Stay on Treatment
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 28 slides
Latest news
New National Survey Found Many People With Sleep Apnea Struggle to Stay on Treatment
Nov 19, 2026
Closed $16.09 (-7.8%) on Nov 20, 2026
Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 16, 2026
Closed $16.28 (-3.8%) on Nov 16, 2026
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2026
Closed $15.10 (+6.6%) on Nov 6, 2026
Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
Oct 12, 2026
Closed $17.83 (-4.3%) on Oct 13, 2026
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Sep 8, 2026
Closed $28.08 (-2.5%) on Sep 9, 2026
Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Aug 3, 2026
Closed $25.71 (+2.8%) on Aug 4, 2026
Apnimed Shares Rise in Initial Trading After Upsized IPO
Jul 31, 2026
Closed $25.00 (+56.3%) on Jul 31, 2026
Apnimed, Inc. on 6ix
- News releases
- 9 in the last 12 months · 9 in all · newest Nov 19, 2026 · oldest 2026
- Decks
- 15 decks · latest September 2026
Where Apnimed, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:APMD · Home listing | NASDAQ | United States | USD |
| BOATS:APMD · This page | BOATS | United States | USD |
Valuation
Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $357.1M USD
- P/E
- Loss
- EV/sales
- 9.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.4×
- Gross margin
- 82.6%
- Operating margin
- −139.9%
- Net margin
- −2.4%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- Under 6 months of closes
Forecasts
4 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 50.00 USD · Analysts' mean
- EPS, year to Dec 2026
- 1.07 · 1 analyst
- Revenue, year to Dec 2026
- 99.37M · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Kevin R. Lind | Chief Executive Officer |
| Michael Kelly | Chief Financial Officer |
| Dennis Molnar | President and Chief Operating Officer |
| Steven Spector | Chief Legal Officer and Head of Corporate Affairs |
| Andrea Werner | Senior Vice President, Global Clinical Operations |
| Jennifer Patterson | Senior Vice President, Human Resources |
| John Yee | Senior Vice President, Medical Affairs |
| Barry Wohl | Chief Business Officer |
| Beth Weinberg | Chief Regulatory and Safety Officer |
| Graham Goodrich | Chief Commercial Officer |
| John Cronin | Chief Medical Officer |
| Luigi Taranto Montemurro | Chief Scientific Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · Before open | −3.8% |
| Q2 2026 | Sep 8, 2026 · After close | −2.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 28 slides | September 2026 |
| Investor Presentation (July 2025) | Investor deck | 21 slides | July 2025 |
| Investor Presentation (May 2025) | Investor deck | 22 slides | May 2025 |
| Investor Presentation (April 2025) | Investor deck | 29 slides | April 2025 |
| Investor Presentation (January 2025) | Investor deck | 28 slides | January 2025 |
| Investor Presentation (December 2024) | Investor deck | 24 slides | Dec 2, 2024 |
| Investor Presentation (May 2024) | Investor deck | 20 slides | May 2024 |
| Investor Presentation (March 2024) | Investor deck | 20 slides | March 2024 |
| Investor Presentation (January 2024) | Investor deck | 20 slides | January 2024 |
| Investor Presentation (November 2023) | Investor deck | 17 slides | November 2023 |
All 15 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2023) | Investor deck | 17 slides | September 2023 |
| Investor Presentation (April 2023) | Investor deck | 16 slides | April 2023 |
| Investor Presentation (January 2023) | Investor deck | 18 slides | January 2023 |
| Investor Presentation (November 2022) | Investor deck | 20 slides | November 2022 |
| JPMorgan Healthcare Conference 2022 | Conference | 21 slides | January 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$220.8M in the latest tranche · US$16 a share · BofA Securities +3 Dealers: BofA Securities (co-lead), Evercore ISI (co-lead), Cantor (co-lead), LifeSci Capital (co-lead) Use of proceeds: To support commercial readiness and the potential U.S. launch of Oxnimbi, if approved by the FDA | Sep 8, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Jul 30, 2026.
- Price
- US$16.00 a share
- Shares offered
- 12,000,000 shares of common stock
- Offering size
- US$192 million
- Underwriters' option
- Up to 1,800,000 more shares
- Listing
- APMD on the Nasdaq Global Select Market
- Underwriters
- BofA Securities, Evercore ISI, Cantor, LifeSci Capital · In the order on the cover
- Shares delivered
- On or about Aug 3, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 1, 2024 |
| Filed publicly | Jul 10, 2026 |
| Amended once | Jul 27, 2026 |
| Shares registered with an exchange | Jul 29, 2026 |
| Declared effective by the SEC | Jul 30, 2026 |
| Final prospectus, with the price | Jul 31, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 31, 2026 |
| EFFECT · Notice that a registration is effective | Jul 30, 2026 |
| S-1MEF · Registration of more shares for the same offering | Jul 30, 2026 |
| CERT · Exchange's certificate of listing | Jul 30, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 29, 2026 |
| S-1/A · Registration statement, amended | Jul 27, 2026 |
| S-1 · Registration statement | Jul 10, 2026 |
| DRS/A · Draft registration statement, amended | Jun 1, 2026 |
| DRS/A · Draft registration statement, amended | Apr 22, 2026 |
| DRS/A · Draft registration statement, amended | Feb 17, 2026 |
All 11 filings
| Filing | Filed |
|---|---|
| DRS · Draft registration statement | Jul 1, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 31, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 38.5M | 8.01M |
| Cost of revenue | 6.69M | 3.37M |
| Gross profit | 31.8M | 4.64M |
| Research and development | 62.1M | 97.4M |
| Selling, general and administrative | 23.5M | 21.5M |
| Operating income | -53.8M | -114.2M |
| Depreciation and amortization | 27.0K | 23.0K |
| EBITDA | -53.8M | -114.2M |
| Income before tax | -932.0K | -108.5M |
| Net income | -932.0K | -111.3M |
| Earnings per share, basic | -0.03 | -2.79 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 41.9M | 68.3M |
| Receivables | 959.0K | 1.11M |
| Current assets | 45.1M | 73.2M |
| Total assets | 72.9M | 109.2M |
| Accounts payable | 1.79M | 3.58M |
| Current liabilities | 110.9M | 42.4M |
| Long-term debt | 40.6M | |
| Total debt | 41.5M | |
| Total liabilities | 445.7M | 357.8M |
| Shareholders' equity | -372.8M | -248.6M |
| Shares outstanding | 26.6M | 39.8M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -77.8M | -110.2M |
| Capital spending | 0 | -70.0K |
| Free cash flow | -77.8M | -110.3M |
| Cash from financing | 51.4M | 51.0K |
| Change in cash | -26.5M | 41.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| 10-Q/A · Quarterly report, amended | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 4, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Sep 8, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Sep 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | Sep 8, 2026 | Results | SEC |
All 61 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 3, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jul 31, 2026 | Offer document | SEC |
| 424B4 · Prospectus | Jul 31, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 31, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Jul 30, 2026 | Insider trade | SEC |
| S-1MEF · Registration of more shares for the same offering | Jul 30, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Jul 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 30, 2026 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Jul 30, 2026 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Jul 29, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 27, 2026 | Offer document | SEC |
| S-1 · Registration statement | Jul 10, 2026 | Offer document | SEC |
| DRS/A · Draft registration statement, amended | May 29, 2026 | Offer document | SEC |
| DRS/A · Draft registration statement, amended | Apr 21, 2026 | Offer document | SEC |
| D | Mar 26, 2026 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Feb 17, 2026 | Offer document | SEC |
| D/A | Dec 8, 2025 | Other filings | SEC |
| D/A | Oct 1, 2025 | Other filings | SEC |
| D | Sep 24, 2025 | Other filings | SEC |
| D | Apr 24, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Jul 1, 2024 | Offer document | SEC |
| D | Nov 8, 2023 | Other filings | SEC |
| D | Dec 23, 2022 | Other filings | SEC |
| D/A | Nov 1, 2022 | Other filings | SEC |
| D | May 10, 2022 | Other filings | SEC |
| D | Mar 25, 2021 | Other filings | SEC |
| D | Apr 7, 2020 | Other filings | SEC |
| D/A | Aug 7, 2019 | Other filings | SEC |
| D/A | Jan 10, 2019 | Other filings | SEC |
| D/A | Aug 9, 2018 | Other filings | SEC |
| D | Jul 6, 2018 | Other filings | SEC |
Cap table
Built by 6ix from Apnimed, Inc.’s releases · as of Sep 30, 2026
- Common shares
- 41,630,779
- Fully diluted
- 41,630,779
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 41,630,779 | Sep 4, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 4, 2026 | 41,630,779 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Paul Sekhri Other companies: vTv Therapeutics Inc. (Chairman of the Board, President and Chief Executive Officer · Since at least Aug 1, 2022); Veeva Systems Inc. (Director · Since at least Jun 22, 2016); Axcella Health Inc (Director · May 19, 2022 – May 19, 2022 · Past); Longboard Pharmaceuticals Inc (Director · Mar 11, 2021 – Dec 2, 2024 · Past); BiomX Inc. (Director · Oct 2, 2020 – Jul 28, 2021 · Past); Enumeral Biomedical Holdings Inc (Director · Dec 9, 2016 – Dec 9, 2016 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Jan 2, 2020 · Past) | Director · Since at least Jul 30, 2026 |
| Paul Fonteyne Other companies: Amylyx Pharmaceuticals, Inc. (Director · Since at least Jan 6, 2022); Apellis Pharmaceuticals, Inc. (Director · Since at least Apr 2, 2020); Covetrus Inc (Director · Jul 1, 2021 – Oct 13, 2022 · Past); AMAG Pharmaceuticals Inc (Director · Oct 8, 2019 – Nov 16, 2020 · Past); Adicet Bio, Inc. (Director · Jan 25, 2018 – Jun 3, 2020 · Past) | Director · Since at least Jul 30, 2026 |
| Kevin Lind Other companies: Avalo Therapeutics, Inc. (Director · Since at least Sep 22, 2025); Longboard Pharmaceuticals Inc (President and CEO, Director · Mar 11, 2021 – Dec 2, 2024 · Past); Arena Pharmaceuticals Inc (Executive VP and CFO · Jun 15, 2016 – Mar 1, 2020 · Past) | Chief Executive Officer · Since at least Jul 30, 2026 |
| John Yee Other companies: Tempest Therapeutics, Inc. (Director · Since at least Jun 4, 2026) | Senior Vice President, Medical Affairs · Since at least Nov 5, 2026 |
| Andrea Werner | Senior Vice President, Global Clinical Operations · Since at least Nov 5, 2026 |
| Barry Wohl | Chief Business Officer · Since at least Nov 5, 2026 |
| Beth Weinberg | Chief Regulatory and Safety Officer · Since at least Nov 4, 2026 |
| Dennis Molnar | President and Chief Operating Officer · Since at least Jul 30, 2026 |
| Graham Goodrich | Chief Commercial Officer · Since at least Nov 5, 2026 |
| Jennifer Patterson | Senior Vice President, Human Resources · Since at least Nov 5, 2026 |
All 15 people
| Person | Seat |
|---|---|
| John Cronin | Chief Medical Officer · Since at least Nov 5, 2026 |
| Lawrence G Miller | Director · Since at least Jul 30, 2026 |
| Luigi Taranto Montemurro | Chief Scientific Officer · Since at least Nov 5, 2026 |
| Michael Kelly | Chief Financial Officer · Since at least Jul 30, 2026 |
| Steven Spector | Chief Legal Officer and Head of Corporate Affairs · Since at least Sep 8, 2026 |
Log in to ask 6ix AI your own questions about Apnimed, Inc.